Drug Profile
Tumour peptide-pulsed dendritic cell vaccine - Tella
Alternative Names: Dendritic-cell-vaccine-Tella; MUC1-WT1-peptide-loaded-dendritic-cell-vaccine-Tella; Peptide-pulsed-dendritic-cell-vaccine-Tella; TLP0-001; Vaccell - Tella; WT1 and MUC1 peptide-pulsed dendritic cell vaccine - TellaLatest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Tella
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Pancreatic cancer
- Phase I/II Biliary cancer; Malignant melanoma
- No development reported Allergic rhinitis; Autoimmune disorders; Liver cancer; Oesophageal cancer
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for phase-I development in Oesophageal-cancer in Japan (Parenteral)
- 15 Feb 2021 Tella completes a phase I/II trial in Biliary cancer (In adults, In the elderly) in Japan (Parenteral) (UMIN000010388)
- 15 Feb 2021 Tella completes a phase I/II trial in Pancreatic cancer (In adults, In the elderly) in Japan (Parenteral) (UMIN000010388)